diabetes glp-1 agonist receptor agonists are increasingly used to treat type 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Evolution of GLP‐1 Receptor Agonists

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating

GLP-1 injected subcutaneously simply took too long to reach receptors on target tissuesDPP-4 degraded the peptide within minutes

Consuming eggs for breakfast may help manage hunger and possibly decrease how much you eat later in the day, contributing further to their beneficial effect on weight management

Available from: 54.Sjstrm L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden , et al

GLP-1 Receptor Agonists: Mechanism and Clinical Equivalence GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor, reducing appetite, slowing gastric emptying, and improving glucose control

These include lifestyle modification requirements (69%), trialing lower-cost medications first (63%) and limiting therapy duration (63%)